X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (28650) 28650
Book Chapter (152) 152
Publication (58) 58
Dissertation (34) 34
Newspaper Article (33) 33
Magazine Article (31) 31
Conference Proceeding (15) 15
Web Resource (10) 10
Book / eBook (3) 3
Reference (2) 2
Streaming Video (2) 2
Trade Publication Article (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rituximab (24648) 24648
humans (19978) 19978
female (10392) 10392
male (10166) 10166
middle aged (8464) 8464
adult (7123) 7123
hematology (6769) 6769
aged (6658) 6658
oncology (6466) 6466
treatment outcome (5776) 5776
antibodies, monoclonal, murine-derived (5164) 5164
therapy (4570) 4570
antibodies, monoclonal - therapeutic use (4304) 4304
antineoplastic combined chemotherapy protocols - therapeutic use (3727) 3727
chemotherapy (3689) 3689
lymphomas (3282) 3282
lymphoma (2956) 2956
antibodies, monoclonal, murine-derived - therapeutic use (2920) 2920
prognosis (2750) 2750
aged, 80 and over (2693) 2693
cancer (2679) 2679
cyclophosphamide (2673) 2673
antineoplastic agents - therapeutic use (2636) 2636
transplantation (2541) 2541
non-hodgkins-lymphoma (2525) 2525
care and treatment (2518) 2518
immunology (2462) 2462
rheumatology (2413) 2413
retrospective studies (2393) 2393
immunologic factors - therapeutic use (2156) 2156
rituximab - therapeutic use (2110) 2110
adolescent (2084) 2084
young adult (2055) 2055
survival (2017) 2017
b-cell lymphoma (1996) 1996
patients (1988) 1988
medicine & public health (1879) 1879
immunosuppressive agents - therapeutic use (1857) 1857
antibodies, monoclonal - administration & dosage (1822) 1822
abridged index medicus (1783) 1783
cyclophosphamide - administration & dosage (1770) 1770
immunotherapy (1740) 1740
antibodies, monoclonal, murine-derived - administration & dosage (1730) 1730
lymphoma, large b-cell, diffuse - drug therapy (1728) 1728
disease (1690) 1690
animals (1650) 1650
efficacy (1636) 1636
medicine, general & internal (1625) 1625
recurrence (1597) 1597
remission induction (1562) 1562
disease-free survival (1526) 1526
analysis (1492) 1492
trial (1491) 1491
follow-up studies (1488) 1488
risk factors (1485) 1485
antineoplastic combined chemotherapy protocols - administration & dosage (1459) 1459
diagnosis (1452) 1452
hemic and lymphatic diseases (1443) 1443
monoclonal antibodies (1402) 1402
drug therapy (1385) 1385
rheumatoid arthritis (1384) 1384
research (1340) 1340
follicular lymphoma (1337) 1337
health aspects (1333) 1333
vincristine - administration & dosage (1333) 1333
antibodies (1299) 1299
child (1288) 1288
cyclophosphamide - therapeutic use (1281) 1281
anti-cd20 monoclonal-antibody (1267) 1267
chronic lymphocytic-leukemia (1263) 1263
doxorubicin - administration & dosage (1257) 1257
lymphocytes b (1196) 1196
b-lymphocytes - immunology (1186) 1186
prednisone - administration & dosage (1167) 1167
rituximab - administration & dosage (1152) 1152
leukemia, lymphocytic, chronic, b-cell - drug therapy (1149) 1149
antibodies, monoclonal - adverse effects (1147) 1147
expression (1134) 1134
pharmacology & pharmacy (1133) 1133
safety (1125) 1125
antineoplastic agents (1111) 1111
time factors (1097) 1097
elderly-patients (1082) 1082
combined modality therapy (1070) 1070
antineoplastic combined chemotherapy protocols - adverse effects (1057) 1057
antigens, cd20 - immunology (1056) 1056
antirheumatic agents - therapeutic use (1053) 1053
remission (1045) 1045
fludarabine (1042) 1042
antimitotic agents (1035) 1035
drug therapy, combination (1013) 1013
immune system diseases (1002) 1002
lymphoma, b-cell - drug therapy (1001) 1001
lymphoma, large b-cell, diffuse - pathology (989) 989
lymphoma, non-hodgkin - drug therapy (979) 979
surgery (977) 977
survival analysis (968) 968
double-blind (961) 961
antibodies, monoclonal, murine-derived - adverse effects (958) 958
clinical trials (956) 956
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (26273) 26273
French (633) 633
German (567) 567
Japanese (463) 463
Spanish (403) 403
Chinese (235) 235
Russian (196) 196
Polish (90) 90
Korean (79) 79
Czech (75) 75
Portuguese (58) 58
Hungarian (54) 54
Italian (44) 44
Turkish (24) 24
Danish (17) 17
Croatian (16) 16
Hebrew (11) 11
Dutch (10) 10
Finnish (7) 7
Norwegian (7) 7
Slovak (6) 6
Slovenian (6) 6
Serbian (5) 5
Swedish (5) 5
Icelandic (4) 4
Indonesian (2) 2
Persian (2) 2
Romanian (2) 2
Arabic (1) 1
Belarusian (1) 1
Bosnian (1) 1
Catalan (1) 1
Estonian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology, ISSN 1462-0324, 04/2018, Volume 57, Issue suppl_3
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Evidence-based medicine | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 9, pp. 1932 - 1938
Abstract Background Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic... 
relapsed/refractory NHL | phase Ib | venetoclax | bendamustine-rituximab | Salvage Therapy - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Rituximab - pharmacokinetics | Bendamustine Hydrochloride - adverse effects | Chemotherapy-Induced Febrile Neutropenia - etiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Bendamustine Hydrochloride - pharmacokinetics | Lymphoma, Non-Hodgkin - pathology | Neoplasm Recurrence, Local - pathology | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Rituximab - adverse effects | Chemotherapy-Induced Febrile Neutropenia - epidemiology | Drug Administration Schedule | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Disease Progression | Sulfonamides - pharmacokinetics | Rituximab - administration & dosage | Maximum Tolerated Dose | Progression-Free Survival | Sulfonamides - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Salvage Therapy - methods | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Drug Resistance, Neoplasm - drug effects | relapsed | refractory NHL | Original | bendamustine–rituximab
Journal Article
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 26, pp. 2517 - 2528
Journal Article
Clinical Rheumatology, ISSN 0770-3198, 12/2017, Volume 36, Issue 12, pp. 2743 - 2750
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 18, pp. 1711 - 1721
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 14, pp. 1331 - 1344
Journal Article